Q-omics provides the consensus-scored RAB20 profile across patient tissues and cancer cell-line models. RAB20 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAB20 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, RAB20 RNA expression shows 17,862 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where RAB20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB20 survival associations across molecular data types. RAB20 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB20 RNA expression–survival associations across cancer types. High RAB20 expression shows unfavorable associations in ACC and LUSC, but favorable associations in KIRC, KIRP, UCEC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAB20 RNA expression.
This table summarizes RAB20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB20 shows lower tumor expression in KICH and LUAD and higher tumor expression in KIRC, HNSC, COAD and STAD. The KICH box plot shows higher RAB20 RNA expression in normal versus tumor tissue (log2 FC = −2.694, t-test p < 0.001).
This table shows molecular features associated with RAB20 in patient tissues and cancer cell lines. In patient samples, RAB20 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
